Summit Therapeutics' Jack West on the company's PD-1xVEGF bi-specific vs Keytruda news
V.P. of Clinical Operations Jack West gives his interpretation of the announcement that Summit's partner Akeso made in China that it beat Keytruda on PFS head-to-head in 1L lung. He shares his opinion of how this data could translate outside of China and what Summit's development plans are currently.